92847-41-1

Basic information

• Product Name: 1-(3-CHLOROPHENYL)-5-OXOPYRROLIDINE-3-CARBOXYLICACID
• Synonyms: 3-pyrrolidinecarboxylic acid, 1-(3-chlorophenyl)-5-oxo-;Albb-010050;1-(3-chlorophenyl)-5-oxopyrrolidine-3-carboxylic acid(SALTDATA: FREE);4-Carboxy-1-(3-chlorophenyl)pyrrolidin-2-one
• CAS NO: 92847-41-1
• Molecular Formula: C₁₁H₁₀ClNO₃
• Molecular Weight: 239.66
• Product Categories: Carboxylic Acids;Pyrrolidines;Carboxylic Acids
• Mol File: 92847-41-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 135-136 °C
• Boiling Point: 540.9°C at 760 mmHg
• Flash Point: 281°C
• Appearance: /
• Density: 1.455g/cm³
• Vapor Pressure: 1.56E-12mmHg at 25°C
• Refractive Index: 1.616
• PKA: 4.33±0.20(Predicted)
• CAS DataBase Reference: 1-(3-CHLOROPHENYL)-5-OXOPYRROLIDINE-3-CARBOXYLICACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-CHLOROPHENYL)-5-OXOPYRROLIDINE-3-CARBOXYLICACID(92847-41-1)
• EPA Substance Registry System: 1-(3-CHLOROPHENYL)-5-OXOPYRROLIDINE-3-CARBOXYLICACID(92847-41-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 92847-41-1(Hazardous Substances Data)

Usage

General Description

1-(3-chlorophenyl)-5-oxopyrrolidine-3-carboxylic acid, also known as 3-Chlorophenylpyrrolidin-3-carboxylic acid, is a chemical compound with a molecular formula C10H9ClNO3. It is a carboxylic acid derivative, which contains a pyrrolidine ring with an acyl functional group. 1-(3-CHLOROPHENYL)-5-OXOPYRROLIDINE-3-CARBOXYLICACID is commonly used as a starting material in various chemical synthesis reactions and also find applications in pharmaceutical and research industries. It is important to handle this compound with care and follow safety guidelines due to its potential health hazards and irritant properties. Overall, 1-(3-chlorophenyl)-5-oxopyrrolidine-3-carboxylic acid is a valuable chemical that plays a crucial role in the production of various important compounds.

InChI:InChI=1/C11H10ClNO3/c12-8-2-1-3-9(5-8)13-6-7(11(15)16)4-10(13)14/h1-3,5,7H,4,6H2,(H,15,16)

Upstream product

• 97-65-4 2-methylenesuccinic acid 
• 108-42-9 3-chloro-aniline 

Downstream Products

• 1422385-97-4 methyl 1-(3-chlorophenyl)pyrrolidine-3-carboxylate 
• 1086374-92-6 1‐(3‐chlorophenyl)pyrrolidine‐3‐carboxylic acid 
• 133747-69-0 Methyl 4-[1-(3-chlorophenyl)-2-pyrrolidon-4-yl]methoxybenzoate 
• 1026916-34-6 Methanesulfonic acid 1-(3-chloro-phenyl)-5-oxo-pyrrolidin-3-ylmethyl ester 
• 133747-68-9 1-(3-Chlorophenyl)-4-hydroxymethyl-2-pyrrolidone 

Relevant articles and documents

Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups

Factor XIa (FXIa) inhibitors are promising novel anticoagulants, which show excellent efficacy in preclinical thrombosis models with minimal effects on hemostasis. The discovery of potent and selective FXIa inhibitors which are also orally bioavailable has been a challenge. Here, we describe optimization of the imidazole-based macrocyclic series and our initial progress toward meeting this challenge. A two-pronged strategy, which focused on replacement of the imidazole scaffold and the design of new P1 groups, led to the discovery of potent, orally bioavailable pyridine-based macrocyclic FXIa inhibitors. Moreover, pyridine-based macrocycle 19, possessing the phenylimidazole carboxamide P1, exhibited excellent selectivity against relevant blood coagulation enzymes and displayed antithrombotic efficacy in a rabbit thrombosis model.

The discovery of new plant activators and scaffolds with potential induced systemic resistance: From jasmonic acid to pyrrolidone

Plants can develop multifaceted system resistance as a result of infection with pathogens, insects, and some specific microbes or after treatment with specific chemicals.1 Among them, systemic acquired resistance (SAR) and induced systemic resi

NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.